There are 413 resources available
Breast conservation and axillary management after neo-adjuvant therapy
Presenter: Oreste Gentilini
Session: Optimal treatment strategies in early breast cancer
Resources:
Slides
Webcast
Luminal HER2 positive vs luminal HER2 negative: Different drivers of endocrine resistance and the role of CDK4/6 inhibitors
Presenter: Luca Malorni
Session: Targeted options for advanced luminal breast cancers
Resources:
Slides
Webcast
186O - Patient-reported outcomes (PROs) from DESTINY-Breast02, a randomized phase 3 study of trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice (TPC) in patients (pts) with HER2-positive (HER2+) metastatic breast cancer (mBC)
Presenter: Tanja Fehm
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast
Invited Discussant 185O and 186O
Presenter: Gustavo Werutsky
Session: Proffered Paper session 1
Resources:
Slides
Webcast
Digital interactions in the management of targeted treatment
Presenter: Ines Vaz Luis
Session: Targeted options for advanced luminal breast cancers
Resources:
Slides
Webcast
Points to consider in the development of biomarkers in the neoadjuvant setting: Regulatory perspectives
Presenter: Jonas Bergh
Session: Selecting biomarkers to inform neoadjuvant strategies
Resources:
Slides
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Optimal treatment strategies in early breast cancer
Resources:
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Targeted options for advanced luminal breast cancers
Resources:
Webcast
Q&A and discussion
Presenter: To be Announced
Session: Proffered Paper session 1
Resources:
Webcast
187O - Capivasertib and fulvestrant for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2- advanced breast cancer (ABC): subgroup analyses from the Phase 3 CAPItello-291 trial
Presenter: Nicholas Turner
Session: Proffered Paper session 1
Resources:
Abstract
Slides
Webcast